Received Aug 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
patient had their 1st dose in 2022; This non-serious case was reported by a nurse via call center representative and described the occurrence of incomplete course of vaccination in a female patient who did not receive Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (patient received first dose in 2022). Concurrent medical conditions included immunocompromised and hiv infection. The patient did not receive the 2nd dose of Shingrix. The patient experienced incomplete course of vaccination (Verbatim: patient had their 1st dose in 2022). The outcome of the incomplete course of vaccination was not applicable. Additional Information: GSK Receipt Date: 15-AUG-2025 The nurse wanted to know if she needs to restart a series if an HIV patient had their 1st dose in 2022, or should she finish the series with just one more dose. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.
HIV infection; Immunocompromised